UAMS basic/translational scientists transcribe cutting-edge research into new identification, treatment, and prevention of cancer, infectious disease, substance abuse and behavioral problems. Researchers work with the American Heart/Stroke Associations, Centers for Disease Control, Dept. of Defense, Food and Drug Administration, National Institutes of Health, National Science Foundation, and other national/international organizations to better the health of Arkansans.
COVID-19 Research
- Funding
- Due to the global COVID-19 pandemic, several national funding opportunities have been issued. Learn more.
- Guidelines
- Find NIH guidance and information on rapidly evolving COVID-19 research impacts.
- As part of the “new normal” for UAMS research, several safety measures to reduce coronavirus risk in labs/research spaces have been enacted. See guidelines for details.
- Research Updates
UAMS Research News
-
UAMS Researcher to Use $991,000 to Improve Health of Arkansans with Food Insecurity and Type 2 Diabetes
FAYETTEVILLE – A University of Arkansas for Medical Sciences (UAMS) researcher recently received a $991,145 grant from the U.S. Department of Agriculture (USDA) to study the nutritional health of low-income individuals with type 2 diabetes. Christopher Long, Ph.D., an assistant professor in the Department of Psychiatry, will use the award from the USDA’s National Institute…
-
Arkansas INBRE Receives 5-Year Funding of $18.4 Million to Promote Biomedical Research Across Arkansas
Arkansas INBRE, which promotes biomedical research with programs for undergraduate students and faculty statewide, has seen its federal funding renewed for $18.4 million over the next five years. While the University of Arkansas for Medical Sciences (UAMS) is the lead institution, INBRE grants and programs have impacted nearly all colleges and universities in the state…
-
UAMS Receives FDA Authorization for Convalescent Plasma Use, Plus Partnerships for Statewide Access
The Food and Drug Administration has authorized the use of convalescent plasma in Arkansas as an experimental treatment for COVID-19 with the University of Arkansas for Medical Sciences (UAMS) as the expanded access treatment program sponsor. With the authorization, UAMS Medical Center is able to use the treatment now without applying for FDA approval for…